SG

Seyyed-Hadi Ghamari

Also known as: Hadi Ghamari, Seyyedhadi Ghamari

World Health Organization, University of Oxford, Shahid Beheshti University of Medical Sciences, Tehran University of Medical Sciences

Research areas: Medicine · Public Health, Environmental and Occupational Health · Global Health and Epidemiology · Global Cancer Incidence and Screening · Diabetes, Cardiovascular Risks, and Lipoproteins

ORCID iD 0000-0001-6028-3303
Follow

About

Dr Seyyed-Hadi Ghamari is an MD, MPH graduate, and DPhil student in Women's and Reproductive Health at the Deep Medicine team, Nuffield Department of Women’s & Reproductive Health, University of Oxford, with academic interests spanning from epidemiological studies to clinical trials in non-communicable diseases (NCDs), cardiometabolic health, health systems performance, and large-scale datasets. He works as a Consultant at Cardiovascular Diseases team of World Health Organisation (Headquarters).

He completed his Medical Doctor (MD) at Shahid Beheshti University of Medical Sciences (SBMU), Tehran (2014–2021) and a Master of Public Health (MPH) at SBMU (2018–2021), with academic attainment equivalent to a UK First-Class Honours (1st), and developed a research programme centred on NCD epidemiology, quality of care, and large-scale health data.

He has been recognised for academic excellence with awards and honors, including
1. Prestigious Clarendon scholarship to support his studies at the University of Oxford
1. Bronze Medalist, 10th Medical Sciences Olympiad (2018) (Basic Sciences – Cell Therapy/CAR T Cells).
2. Scholarships for MD and MPH training (SBMU) and recognition as exceptional talent.

He has extensive experience delivering national and international population-health programmes, including work with the Noncommunicable Diseases Research Center (NCDRC), Tehran University of Medical Sciences (2020–present), contributing to policy-facing outputs, multi-institutional collaborations (including with the World Health Organization), and high-impact publications.

He has published in leading international journals, including:
The BMJ (multicentre phase 3 clinical trial)
eClinicalMedicine (Part of The Lancet Discovery Science)
Lancet Planetary Health
Journal of the American Heart Association
Scientific Reports

He has published 34 original research articles (excluding large collaboration-network papers) as a mainline author (10+ as first or corresponding author).

He has contributed to high-impact outputs and projects including:
1.WHO facility-based NCD patient and programme monitoring guidance, where he was core methods team and led a Donabedian-model (structure–process–outcome) indicator framework and a systematic review of indicator validation studies, alongside an accompanying EClinicalMedicine paper.
2. Large randomised trials, including the BMJ phase III trial (>20,000 participants), plus additional RCT work across related programmes.
3. National and international analyses on NCD burden and quality of care, and COVID-19 hospital data studies (including work using datasets of >600,000 patients).

His research interests include:
1. Hypertension & Quality of Care: improving identification of uncontrolled/resistant hypertension, longitudinal tracking, and benchmarking of care using routine health-system data.
2. Health Systems Performance & NCD Monitoring: Designing and validating facility-level indicators and translating them into implementable monitoring guidance (WHO-aligned).
3. National NCD Surveillance (WHO STEPs): Supporting design, delivery, and curation of national cardiometabolic risk-factor surveillance and its use in global analyses.
4. Large-scale Epidemiology & Global Collaboration: Contributing to international consortia (NCD-RisC; Global Burden of Disease) through study design, analysis planning, interpretation, and writing.

Key funded research projects he has contributed to include:
1. Facility-based NCD patient & programme monitoring framework (Co-investigator; WHO Headquarters, 2021–2024)
2. WHO STEPs survey in Iran (Co-investigator; Iranian NIHR, 2019–2021)
3. Cost of Diabetes Type II (CODII) in Iran (Co-investigator; Novo Nordisk Pars, 2019–2023)
4. Optimisation of ventilation-therapy prioritisation strategies in hospitalised COVID-19 (Co-investigator; WHO Country Office Iran, 2020–2023).

Employment

Education

Projects & Funding

  • NCD facility-based patient and program monitoring framework World Health Organization
  • Cost of Diabetes Type II in Iran (CODII) NovoNordisk Foundation Center for Basic Metabolic Research
  • STEPwise approach to non-communicable diseases (NCD) risk factor surveillance (STEPs) 2021 Iran National Institute of Health Research

Publications (94)